Related Experiment Video
Updated: Jun 17, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Predicting short term response to anti-inflammatory therapy in young children with asthma
Stefan Zielen1, Martin Christmann, Magdalena Kloska
1Allergologie, Pneumologie und Mukoviszidose, Klinikum der Johann Wolfgang-Goethe-Universität, 60590 Frankfurt, Germany.
Insights
Predicting asthma treatment response in children is possible using lung function tests. Pre-bronchodilatory Forced Expiratory Volume in one second (FEV1) and airway reversibility effectively indicate short-term response to inhaled corticosteroids (ICS) and montelukast.
Area of Science:
- Pediatric Pulmonology
- Asthma Management
- Biomarker Discovery
Background:
- Current anti-inflammatory asthma treatments for young children include inhaled corticosteroids (ICS) and montelukast (LTRA).
- Identifying predictors of treatment response is crucial for optimizing pediatric asthma care.
Purpose of the Study:
- To identify biomarkers that predict short-term (6-week) response to ICS and LTRAs in children with asthma.
- To evaluate the efficacy of pre-bronchodilatory FEV1 and airway reversibility as predictive markers.
Main Methods:
- 102 children (4-7 years) with episodic asthma were enrolled.
- 45 symptomatic children were randomized to receive either montelukast or fluticasone for 6 weeks.
- Biomarkers including FEV1, airway reversibility, methacholine challenge, eNO, allergy status, IgE levels, and eosinophils were assessed.
Main Results:
- Both montelukast and fluticasone showed equal effectiveness in improving FEV1 (p = 0.44).
- Pre-bronchodilatory FEV1 (p < 0.001) and airway reversibility (p = 0.04) at randomization strongly correlated with favorable treatment response.
- Other tested biomarkers, including exhaled nitric oxide and IgE levels, were not predictive.
Conclusions:
- Pre-bronchodilatory FEV1 and airway reversibility are promising indicators for predicting short-term anti-inflammatory therapy response in young children with asthma.
- These lung function parameters may aid in tailoring asthma treatment strategies for pediatric patients.
Background:
Currently available anti-inflammatory treatment for young children with asthma includes inhaled corticosteroids (ICS) and the leukotriene receptor antagonist (LTRA) montelukast.
Objective:
To evaluate potential biomarkers of predicting short-term (6-week) response to ICS and LTRAs in children with asthma.
Methods:
A total of 102 children aged 4 to 7 years with episodic asthma were enrolled in an open labelled single-centre study. Biomarkers and asthma characteristics were evaluated as predictors of treatment. Of 102 patients 45 became symptomatic during observation and were randomised to treatment either to montelukast or fluticasone for 6 weeks.
Results:
Forced Expiratory Volume in one second (FEV1) increased with both treatments: FEV1 at randomisation was 90.2% and after therapy 106.8% with fluticasone vs. 90.8% and 103.7% for montelukast, respectively, showing that montelukast and fluticasone were equally effective in this age group (p = 0.44). Strong correlations to a favourable treatment response were pre-bronchodilatory FEV1 (p < 0.001) and airway reversibility (p = 0.04) at time of randomisation. None of the other biomarkers (methacholine testing, exhaled nitric oxide [eNO], presence of allergy, total Immunoglobulin E [IgE], cumulative specific IgE, eosinophils and parental smoking) were predictive.
Conclusion:
Despite the small sample size and the open-label design, the study suggests that the use of pre-bronchodilatory FEV1 and airway reversibility appears to be a good indicator of short-term anti-inflammatory therapy in young children with asthma.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma I: Introduction
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Asthma-I: Introduction
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

